Lates News

AstraZeneca's new small molecule drug factory in Wuxi officially started construction on May 8th. The new factory has a total investment of 475 million US dollars, covers an area of approximately 30,000 square meters, and will be equipped with two sets of advanced tablet continuous manufacturing process equipment and seven sustainable drug packaging production lines. It will mainly produce AstraZeneca's cardiovascular innovative drugs in the pipeline and is expected to start production in the fourth quarter of 2028. This is a further deepening of AstraZeneca's supply chain layout in China following the completion of the main body of the first phase of the construction of the Qingdao inhaled aerosol production supply base last month (First Financial Daily).